

Bing-Wen Zou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789971/publications.pdf>

Version: 2024-02-01

43
papers

1,301
citations

566801

15
h-index

377514

34
g-index

44
all docs

44
docs citations

44
times ranked

1587
citing authors

#	ARTICLE	IF	CITATIONS
1	A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. <i>Journal of Colloid and Interface Science</i> , 2022, 607, 1516-1526.	5.0	41
2	Preoperative Chemotherapy for Limited-stage Small Cell Carcinoma of the Esophagus. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1220-1228.	0.7	6
3	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2589-2598.	1.2	9
4	Magic of Architecting Oligo-DNAs: 3D Structure-Dependent Stability and Programmable Specificity to Tumor Cells. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	9
5	Functionalized chitosan as a promising platform for cancer immunotherapy: A review. <i>Carbohydrate Polymers</i> , 2022, 290, 119452.	5.1	30
6	Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21174-e21174.	0.8	0
7	Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20608-e20608.	0.8	0
8	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	0.8	3
9	Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188749.	3.3	10
10	Single nucleotide polymorphisms within NFKBIA are associated with nasopharyngeal carcinoma susceptibility in Chinese Han population. <i>Cytokine</i> , 2021, 138, 155356.	1.4	4
11	The pathogenesis and diagnosis of sepsis post burn injury. <i>Burns and Trauma</i> , 2021, 9, tkaa047.	2.3	63
12	Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 621181.	1.6	8
13	Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1072-1083.	1.0	2
14	A Tumor-Specific Ferric-Coordinated Epigallocatechin-3-gallate cascade nanoreactor for glioblastoma therapy. <i>Journal of Advanced Research</i> , 2021, 34, 29-41.	4.4	22
15	Secondary infections after diagnosis of severe radiation pneumonitis (SRP) among non-small cell lung cancer patients: pathogen distributions, choice of empirical antibiotics and the value of empirical antifungal treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	6
16	Folic acid-functionalized tea polyphenol as a tumor-targeting nano-drug delivery system. <i>Materials and Design</i> , 2021, 206, 109805.	3.3	15
17	Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 521, 210-223.	3.2	20
18	MIR-4295 facilitates cell proliferation and metastasis in head and neck squamous cell carcinoma by targeting NPTX1. <i>Genes and Immunity</i> , 2020, 21, 4-12.	2.2	15

#	ARTICLE	IF	CITATIONS
19	NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 227.	7.1	386
20	Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lungâ€molGPA) in a Chinese cohort: A retrospective study of multiple institutions. <i>Cancer Medicine</i> , 2020, 9, 8772-8781.	1.3	2
21	Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs. <i>Molecular Biomedicine</i> , 2020, 1, 4.	1.7	14
22	Engineering a pH/Glutathione-Responsive Tea Polyphenol Nanodevice as an Apoptosis/Ferroptosis-Inducing Agent. <i>ACS Applied Bio Materials</i> , 2020, 3, 4128-4138.	2.3	31
23	Novel <i>NLRC4â€ALK</i> and <i>EML4â€ALK</i> double fusion mutations in a lung adenocarcinoma patient: A case report. <i>Thoracic Cancer</i> , 2020, 11, 1695-1698.	0.8	6
24	Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?. <i>Thoracic Cancer</i> , 2020, 11, 631-639.	0.8	11
25	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	15.2	322
26	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. <i>Stem Cell Research</i> , 2019, 40, 101536.	0.3	18
27	Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 1-5.	0.9	23
28	Adjuvant gamma knife surgery and image-guided, intensity-modulated radiation therapy for the treatment of sacral chordomas. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 74-79.	0.3	4
29	Potent Anti-adhesion Barrier Combined Biodegradable Hydrogel with Multifunctional Turkish Galls Extract. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 24469-24479.	4.0	36
30	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	0.8	4
31	Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression. <i>Journal of Cancer</i> , 2017, 8, 3682-3688.	1.2	3
32	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	0.8	22
33	Multicentric randomized phase II trial of gamma knife surgery (GKS) versus image-guided, intensity-modulated radiation therapy (IG-IMRT) in patients with sacrococcygeal chordoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11033-11033.	0.8	0
34	Neutrophil-to-Lymphocyte and Aspartate-to-Alanine Aminotransferase Ratios Predict Hepatocellular Carcinoma Prognosis after Transarterial Embolization. <i>Digestive Disease Interventions</i> , 2017, 01, .	0.3	0
35	Overexpression of miR-96 promotes cell proliferation by targeting FOXF2 in prostate cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 7596-7602.	0.5	0
36	Associations of LIM kinase1 (LIMK1) gene single nucleotide polymorphisms with prostate cancer susceptibility in Chinese population. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9725-9734.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4535-4544.	3.3	25
38	Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4545-4552.	3.3	21
39	Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients. <i>Medicine (United States)</i> , 2016, 95, e3507.	0.4	18
40	Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient. <i>Molecular and Clinical Oncology</i> , 2016, 5, 382-384.	0.4	7
41	Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes. <i>Thoracic Cancer</i> , 2016, 7, 515-521.	0.8	12
42	Salvage treatment with erlotinib after gefitinib failure in advanced non–small–cell lung cancer patients with poor performance status: A matched–pair case–control study. <i>Thoracic Cancer</i> , 2012, 3, 27-33.	0.8	4
43	A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Nodal Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 321-328.	0.4	60